Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Prelude Therapeutics ( (PRLD) ).
On April 20, 2026, Prelude Therapeutics announced new preclinical data for its lead candidate PRT13722, a first-in-class, orally bioavailable and highly selective KAT6A degrader being developed for HR-positive/HER2-negative breast cancer. The data, presented at the AACR Annual Meeting 2026, showed that PRT13722 delivered more complete disruption of KAT6A pathways than dual KAT6A/B inhibitors and drove durable complete tumor regressions in xenograft models at well-tolerated doses.
The preclinical results also indicated strong synergy with endocrine therapy, CDK4/6 inhibitors and PI3Kα inhibitors, including in therapy-resistant and ESR1-mutant breast cancer models, alongside an improved hematological safety profile versus prifetrastat. Prelude said PRT13722 remains on track for an investigational new drug filing by mid-2026, with a Phase 1 trial expected in the second half of 2026, underscoring the program’s potential to support new combination regimens and bolster the company’s position in precision oncology.
The most recent analyst rating on (PRLD) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Prelude Therapeutics stock, see the PRLD Stock Forecast page.
Spark’s Take on PRLD Stock
According to Spark, TipRanks’ AI Analyst, PRLD is a Neutral.
The score is held back primarily by weak financial performance (large losses and ongoing cash burn despite improvement) and limited valuation support (negative P/E, no dividend). Offsetting factors include strong recent technical momentum and generally positive corporate developments, though financing actions introduce dilution risk.
To see Spark’s full report on PRLD stock, click here.
More about Prelude Therapeutics
Prelude Therapeutics Incorporated is a Nasdaq-listed precision oncology company focused on developing innovative cancer medicines for areas of high unmet need. Its pipeline centers on highly selective KAT6A degraders and JAK2V617F mutant-selective inhibitors, and it is also advancing next-generation degrader antibody conjugates that leverage targeted protein degradation.
The company aims to deliver transformative targeted therapies, particularly in hormone receptor-positive breast cancer, by creating first-in-class small molecules and novel biologic conjugates. Prelude’s strategy targets clinically validated pathways with more selective, potent, and tolerable agents that can be combined with existing standards of care to extend the reach of precision medicine.
Average Trading Volume: 300,683
Technical Sentiment Signal: Buy
Current Market Cap: $347.8M
See more data about PRLD stock on TipRanks’ Stock Analysis page.